Literature DB >> 20450911

Zonisamide: aspects in neuroprotection.

Thomas W Rösler1, Oscar Arias-Carrión, Günter U Höglinger.   

Abstract

Zonisamide is widely used as an antiepileptic drug. Two studies published recently in Experimental Neurology focus on the drug's neuroprotective effect. In the present commentary, we discuss the significance of their findings and aspects of zonisamide in neuroprotection. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20450911     DOI： 10.1016/j.expneurol.2010.04.017

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


  5 in total

1.  Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex.

Authors:  Claudia Binda; Milagros Aldeco; Andrea Mattevi; Dale E Edmondson
Journal:  J Med Chem       Date:  2010-12-22       Impact factor: 7.446

2.  Consumption of pharmaceuticals in primary non-Alzheimer's degenerative dementias : a cross-sectional study by the Registry of Dementias of Girona (ReDeGi).

Authors:  Secundino López-Pousa; Oriol Turró-Garriga; Laia Calvó-Perxas; Olga Carmona; Jordi Gich; Elisabet Alsina; Fabià Màrquez; Marta Viñas; Josefa Turbau; Joan Vilalta-Franch; Anna Maria Roig; Josep Garre-Olmo
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

3.  Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain.

Authors:  Yasemin Topçu; Erhan Bayram; Seda Ozbal; Uluç Yiş; Kazım Tuğyan; Pakize Karaoğlu; Abdullah Kumral; Osman Yılmaz; Semra Hız Kurul
Journal:  Neurol Sci       Date:  2014-06-11       Impact factor: 3.307

4.  Protective effects of zonisamide against rotenone-induced neurotoxicity.

Authors:  Salvatore Condello; Monica Currò; Nadia Ferlazzo; Gregorio Costa; Giuseppa Visalli; Daniela Caccamo; Laura Rosa Pisani; Cinzia Costa; Paolo Calabresi; Riccardo Ientile; Francesco Pisani
Journal:  Neurochem Res       Date:  2013-10-20       Impact factor: 3.996

5.  Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.

Authors:  Shigeki Arawaka; Shingo Fukushima; Hiroyasu Sato; Asuka Sasaki; Kaori Koga; Shingo Koyama; Takeo Kato
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.